Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults with Major Depressive Disorder (MDD) (SAVITRI)
Official Title
Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults with Major Depressive Disorder (MDD) (SAVITRI)Purpose
The purpose of this study is to evaluate the effectiveness and safety of NBI-1065845 compared with placebo. In addition to the study drug, participants will continue their normal antidepressant medications. The main goal of this study is to examine the improving symptoms of depression.
The duration of the study will last 14 weeks, including up to 4 weeks of screening, 8 weeks of study drug dosing, and a follow-up period of 2 weeks.
Could this study be right for you?
• Aged 18-65 years old
• Have a diagnosis of Major Depressive Disorder (MDD)
• Currently depressed
• Poor response to antidepressant treatment